Inhalation systems | Features of available devices | DPI | Turbohaler® | Use of Turbohaler

Characteristics of the Turbuhaler®‚ dry powder inhaler

The number of studies investigating characteristics of the Turbuhaler® exceeds research on any other dry powder inhaler. It is one of the DPIs with a relatively high intrinsic resistance. Therefore formation of the fine particle fraction highly depends on the flow achieved within the system. Since highly correlates with particle size interindividual variability of efficacy must be anticipated.

With a reasonably high inspiratory flow of 60 l/min a large fraction of very small particles is generated (in average 2.5 µm). However in comparison to a low resistance DPI the same inspiratory force yields a flow of 60 l/min through the Aerolizer® and of 28 l/min through the Turbuhaler®. Under these conditions the Aerolizer® emits 82% of the metered dose with an average particle size of 4.26 µm while the Turbuhaler® releases 58% of the metered dose with an average particle size of 5.5 µm.

The Turbuhaler® is approved for the drugs budesonide (Pulmicort®, Spirocort®), formoterol (Oxis®), terbutaline (Aerodurâ®, Bricanyl®) and a combination of budesonide plus formoterol (Symbicort®).

Turbuhaler Photo

Correct use of the Turbuhaler®

Unscrew and lift off the cover from the mouthpiece.
Hold the inhaler upright and twist grip forwards and backwards as far as it will go. You should hear a click.
Breathe out gently, put the mouthpiece between your lips and breathe in as deeply as possible.
Even when a full dose is taken there may be no taste.
Remove the inhaler from your mouth and hold breath for about 10 seconds.
Replace the cover.


Malton A, Sumby BS, Smith IJ. A comparison of in vitro drug delivery from two multidose powder inhalation devices. 1995. Eur J Clin Res; 7: 177-193

Voshaar T. Therapie mit Aerosolen. 2005. Uni-Med: Bremen

Weuthen T, Roeder S, Brand P, Müllinger B, Scheuch G. In vitro testing of two formoterol dry powder inhalers at different flow rates. 2002. Journal of Aerosol Medicine; 15 (3): 297-303

Select language



Do you have questions?
Contact our experts...


Related Pages